Syros Pharmaceuticals (SYRS) - יחס מחיר להכנסות חזויות
Syros Pharmaceuticals (SYRS) is developing advanced gene expression modulation methods to combat hematologic malignancies, mitigating risks through research diversification. The GURU.Markets platform reports the firm's forward P/S, where the 8.20 mark characterizes this parameter. Despite fierce competition with pharma behemoths, Syros Pharmaceuticals is actively expanding its drug portfolio, planning the launch of a therapy for acute myeloid leukemia by 2026.
SYRS (Syros Pharmaceuticals, Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים
High binary risks for Syros Pharmaceuticals (SYRS) due to its dependence on a single leukemia drug make the valuation critically dependent on future cash flows. By analyzing the projected market cap-to-revenue ratio, an investor compares the current market price of the business with expected sales volume, allowing for a mathematical assessment of whether the asset is overvalued or undervalued and determining capital resilience during periods of volatility.
